TSS
NKTR icon

Two Sigma Securities’s Nektar Therapeutics NKTR Stock Holding History

Two Sigma Securities’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,844
Closed -$25.7K – 1966
2024
Q4 		$25.7K Buy
1,844
+664
+56% +$11.7K ﹤0.01% 1272
2024
Q3 		$23K Sell
1,180
-241
-17% -$4.59K ﹤0.01% 2475
2024
Q2 		$26.4K Buy
+1,421
New +$29.9K ﹤0.01% 2656
2024
Q1 		– Sell
-1,436
Closed -$12.2K – 3417
2023
Q4 		$12.2K Buy
+1,436
New +$10.9K ﹤0.01% 2797
2023
Q1 		– Sell
-1,180
Closed -$40K – 3063
2022
Q4 		$40K Buy
1,180
+269
+30% +$13K ﹤0.01% 2192
2022
Q3 		$44K Sell
911
-785
-46% -$46.7K ﹤0.01% 2198
2022
Q2 		$97K Buy
+1,696
New +$107K ﹤0.01% 1758
2020
Q1 		– Sell
-1,030
Closed -$333K – 1995
2019
Q4 		$333K Buy
+1,030
New +$299K ﹤0.01% 1723

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Two Sigma Securities's NKTR Position: Q1 2025 in Review

Two Sigma Securities sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 1,844 shares — an estimated $25.7K sold.

Two Sigma Securities first reported a position in NKTR in Q4 2019 and held it in 8 quarters. The position peaked at $333K in Q4 2019. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

  • Two Sigma Securities reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 1,844 Nektar Therapeutics shares in Q1 2025, an estimated $25.7K.
  • Two Sigma Securities first reported a position in Nektar Therapeutics in Q4 2019 and held it in 8 quarters.
  • Two Sigma Securities's Nektar Therapeutics position peaked at $333K in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.